Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date
Mandate

Vinge has advised Fidelio Capital in connection with the establishment of its largest fund to date

June 08, 2023 Employment and Benefits Banking and Finance Corporate Tax Private Funds M&A

The fund – which is Fidelio Capital’s third – has secured more than EUR 1 billion in total capital commitments from an international investor base, which is more than triple the size of the total capital commitments of its previous investment mandate.

Fidelio Capital was founded by Gabriel Fitzgerald in 2010 and focuses on investments in companies without being limited by a pre-determined investment horizon or geographical border, in which it can be an active owner. Through its investment strategy, Fidelio Capital has generated market leading returns, with an average gross IRR of 80% since inception.

Vinge’s team primarily consisted of Mattias Schömer, Jonas Bergström, Jesper Ottergren, Martin Cronsioe, Viveka Classon, Malin Malm Waerme, Fredrik Dahl, Anton Sjökvist, Emelie Svanberg, Semir Omerbasic and Viktoria Wnuk.

 

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025